CNX Therapeutics Secures Debt Facility to Fuel Acquisition DriveNewsPress Release
CNX Therapeutics has secured its first debt facility from Credit funds managed by Ares Management, a global alternative investment manager.
CNX Therapeutics has secured its first debt facility from Credit funds managed by Ares Management, a global alternative investment manager.
CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.
CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.
CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.
CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.
On Saturday 16th September, a day blessed by the last of the beautiful summer weather, a pioneering team of employees – none of whom have ever previously competed in any kind of sporting event – bravely represented CNX at the Impetus Private Equity Triathlon! By participating in the triathlon CNX raised money for Impetus, an organisation what works to transform the lives of young people from disadvantaged backgrounds by making sure they get the right support to succeed in school, in work and in life.
What is Pre-eclampsia? Pre-eclampsia is a pregnancy complication characterised by high blood pressure and signs of damage to organ systems, most often the liver and kidneys. It usually begins after 20 weeks of pregnancy and in women whose blood pressure had previously been normal. Although less common, pre-eclampsia can also occur four to six weeks […]
August has been a very exciting month for CNX; we have welcomed four new faces to the team! Our recent product acquisitions mean it’s vital to have a talented and dynamic team in in place as we expand our portfolio and work towards our goal of becoming a leading provider of critical medicines. Joining our […]
London, August 10th 2023 – CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients, is pleased to announce that it has successfully completed the acquisition of four cancer support products from Clinigen Limited (“Clinigen”), a global pharmaceutical services company. […]
Copyright © 2023 CNX Therapeutics. All rights reserved.
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy and Cookie Notice
CNX Therapeutics to expand CNS portfolio through the acquisition of two established brands from SanofiPress Release
CNX Therapeutics is pleased to announce that it has successfully completed the acquisition of two CNS products from Sanofi SA, a global healthcare company.